Innate Pharma proposes to its shareholders to transform its corporate governance structure into a board of directors and to change its composition
Innate Pharma to hold its Annual General Meeting of shareholders on May 22, 2025
Innate Pharma to participate in the 2025 Stifel Virtual Targeted Oncology Forum
Innate Pharma reports full year 2024 financial results and business update
Innate Pharma highlights antibody drug conjugate IPH4502 abstract selected for the AACR 2025 annual meeting
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Innate Pharma announces conference call and webcast for full year 2024 financial results
Innate Pharma To Participate In The 2025 Leerink Partners Global Healthcare Conference
Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome
Innate Pharma announces first patient dosed in Phase 1 study of its Nectin-4 targeting antibody drug conjugate IPH4502 in selected advanced solid tumors
